SCHEMBL21484752

SCHEMBL21484752

CC(=O)Nc1ccc(CC(C#N)C(=O)Nc2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 18/20 0.71
MEN1 O00255 2/20 0.58
ALDH1A1 P00352 2/20 0.58
LMNA P02545 2/20 0.58
MAPT P10636 2/20 0.58
KMT2A Q03164 2/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GAA P10253 1/20 0.58
PKM P14618 1/20 0.58
RAB9A P51151 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484666 0.83 MRE11 (1.00) MRE11
SCHEMBL21484667 0.82 MRE11 (1.00) MRE11
SCHEMBL21484626 0.81 MRE11 (1.00) MRE11
SCHEMBL21484684 0.80 MRE11 (0.79) MRE11
SCHEMBL21484688 0.80 MRE11 (0.72) MRE11
SCHEMBL21484706 0.79 MRE11 (1.00) MRE11
SCHEMBL21484655 0.78 MRE11 (1.00) MRE11
SCHEMBL21484595 0.78 MRE11 (1.00) MRE11
SCHEMBL21484604 0.77 MRE11 (1.00) MRE11
SCHEMBL1822161 0.76 KMT2A (0.73) MEN1ALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 MRE11 86/4885MEN1 1573/4885ALDH1A1 1635/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 MRE11 86/4885MEN1 1573/4885ALDH1A1 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.